BeiGene said Antaishi (tarlatamab injection), the first and currently only DLL3×CD3 bispecific T‑cell engager co‑developed and to be commercialized with Amgen, received approval from China’s National Medical Products Administration (NMPA) for adults

2026-05-29

BeiGene said Antaishi (tarlatamab injection), the first and currently only DLL3×CD3 bispecific T‑cell engager co‑developed and to be commercialized with Amgen, received approval from China’s National Medical Products Administration (NMPA) for adults with extensive‑stage small‑cell lung cancer (ES‑SCLC) who progressed after one prior systemic therapy, including platinum‑based chemotherapy.